Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells

Deok-Soo Son1*, Syeda M Kabir1, Yuanlin Dong1, Eunsook Lee2 and Samuel E Adunyah1

Abstract

Background: Ovarian cancer, an inflammation-associated cancer, is the fifth leading cause of cancer deaths in women. The malignancy produces a large amount of tumor necrosis factor (TNF) which promotes a proinflammatory tumor microenvironment. In addition, the epidermal growth factor receptor (EGFR) is frequently overexpressed in high-grade ovarian cancer, which likely aggravates cancer progression. Since ovarian cancer progression is closely associated with chemokine networks driven by inflammation or EGFR activation, we investigated the chemokine signatures elicited by EGF and TNF in ovarian cancer cells to determine their individual profiles and if there was in fact some kind of synergy between their actions on the chemokine network.

Methods: We used a PCR array for the chemokine network to examine the signature of chemokines and their receptors elicited by EGF and TNF in four ovarian cancer cell lines (OVCAR-3, SKOV-3, CaOV-3 and TOV-21G).

Results: The chemokine network revealed that ovarian cancer cells commonly expressed high levels of proinflammatory chemokines such as CCL20, CXCL1-3 and CXCL8 in response to EGF or TNF. However, the responsiveness to EGF or TNF displayed a cell line specific pattern. Although OVCAR-3 and SKOV-3 cells were responsive to either EGF or TNF, their TNF responsiveness was dominant. On the other hand, CaOV-3 and TOV-21G cells were responsive to EGF but less to TNF, probably due to the high levels of non-canonical nuclear factor (NF)-κB components such as IKKa and p52 in these cell lines compared to OVCAR-3 and SKOV-3 cells. Among chemokine receptors, only CXCR5 was responsive to EGF or TNF in CaOV-3 cells. Finally, CCL20 and CXCL8 responded synergistically in response to EGF and TNF in OVCAR-3 and SKOV-3 cells.

Conclusion: Our results indicate that CCL20, CXCL1-3 and CXCL8 are the primary chemokines induced by EGF or TNF and are elicited in these ovarian cancer cells via NF-κB, Akt and Erk signaling pathways. Of interest, there was a synergistic response in terms of CCL20 and CXCL8 levels, when OVCAR-3 and SKOV-3 cells were exposed to EGF plus TNF. Targeting these proinflammatory chemokines may be a promising therapeutic strategy for ovarian cancer with abundant TNF and EGFR activation patterns.

Keywords: Chemokines, NF-κB, TNF, EGF, Ovarian cancer

Background

Inflammation-associated ovarian cancer is the fifth leading cause of cancer deaths among women. Chronic infection and inflammation are considered to be among the most important epigenetic and environmental factors contributing to tumorigenesis and cancer progression [1-3]. Ovarian cancer cells highly express highly tumor necrosis factor (TNF), indicating the importance of TNF as a regulator of the proinflammatory tumor microenvironment in this malignancy [3-6]. Thus blockade of the TNF network using neutralizing antibodies or siRNA reduces the ovarian cancer burden [7]. Particularly, TNF regulates chemokine networks through the nuclear factor-κB (NF-κB) signaling pathway. Chemokines are critical mediators of cell migration into and out of the tumor microenvironment and represent major players in cancer progression and metastasis [8,9]. In our previous study, inflammatory agents including bacterial endotoxin lipopolysaccharide (LPS) and proinflammatory cytokines interleukin-1 (IL-1) and TNF, induced CXCL1-3 and CXCL8 in ovarian cancer cells by involving NF-κB signaling.
In addition, those cells with a high endogenous expression of TNF expressed higher levels of CXCR4 than cells with a low TNF expression level [11].

The ErbB/EGFR family of receptors consists of four structurally-related type 1 transmembrane tyrosine kinase receptors: EGFR (ErbB1, HER1), ErbB2 (HER2, neu), ErbB3 (HER3) and ErbB4 (HER4) [12,13]. Activation of ErbB/EGFR tyrosine kinase receptors recruits multiple signaling pathways which play important roles in cell proliferation, survival, adhesion, motility, invasion and angiogenesis [12,13]. EGFR is frequently overexpressed in high-grade malignant ovarian cancer [14,15]. Because of the multiple signaling processes originating from EGFR activation, EGFR overexpression has been correlated with a poor prognosis and a decreased therapeutic responsiveness in patients with ovarian cancer [12]. The phosphatidylinositol 3-kinase (PI3K) which acts as a main downstream signaling pathway for EGF is frequently activated, leading to increased cell survival. Furthermore, EGFR activation may also involve chemokine networks through its downstream signaling pathways. CXCL1 and CXCL8, in particular, have been identified as secreted proteins regulated by EGF and the PI3K pathway in ovarian cancer cell lines [16]. In addition, EGF enhances the expression of CXCR4 as well as migration of ovarian cancer cells [17].

These limited reports indicate that ovarian cancer progression is closely associated with chemokine networks driven by inflammation or EGFR activation. Therefore it is important to identify which chemokines are primarily regulated by TNF and EGF in order to devise a therapeutic strategy based on the chemokine signature seen in this malignancy. Thus the present study was designed to assess the characteristics of the chemokine profiles elicited by EGF and TNF, and determine if they induce any synergistic effects with respect to key chemokines in ovarian cancer cell lines. For the purposes of this study, we evaluated four such lines: OVAR-3, SKOV-3, CaOV-3 and TOV-21G.

**Methods**

**Reagents**

Recombinant human TNF and EGF were obtained from R&D Systems (Minneapolis, MN, USA). Antibodies were purchased from the following vendors: ErbB isoform, p65 and β-actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and NF-κB family, IKK isoforms, IκB, Akt, Erk and their phosphorylated forms from Cell Signaling Technology (Beverly, MA, USA). The PCR array for customized human chemokines, specific PCR primers for CCL2, CCL20, CXCL1-3, CXCL8, CXCL16, CXCR5, β-actin, and SYBR® Green Master Mix came from SABiosciences/Qiagen (Frederick, MD, USA). Chemiluminescent detection kits were from GE Healthcare (Piscataway, NJ, USA). Penicillin G/streptomycin was purchased from Sigma (St. Louis, MO, USA) and Lipofectamine 2000 and all liquid culture media were acquired from Invitrogen (Grand Island, NY, USA). BAY-11-7082, LY294002 and PD98059 were purchased from Cayman Chemical (Ann Arbor, MI, USA). The Luciferase Reporter Assay System was obtained from Promega (Madison, WI, USA).

**Cell lines, cell culture, and media additions**

The human ovarian cancer cell lines OVCAR-3, SKOV-3, CaOV-3 and TOV-21G were purchased from the American Type Culture Collection (ATTC, Manassas, VA, USA). Human cancer cells (approximately 5 × 10⁴ cells/ml) were cultured at 37°C in a water-saturated atmosphere of 95% air and 5% CO² in 24- or 6-well plates with RPMI medium containing 10% fetal bovine serum (FBS) with penicillin (100 U/ml)/streptomycin (100 U/ml). After an overnight culture to allow cellular attachment to the plates, the medium was removed and fresh medium without FBS was added to remove the effects of serum, per se. Where indicated, vehicle (phosphate-buffered saline, PBS), 10 ng/ml EGF, 10 ng/ml TNF, or a combination of EGF and TNF was added, and incubations continued for the indicated time periods.

**PCR array and real-time PCR**

After isolating total RNA and eliminating genomic DNA, reverse transcription reactions were performed at 42°C for 15 min followed by 94°C for 5 min. According to manufacturers’ instructions, a real-time PCR was performed using a Bio-Rad CFX96 (Hercules, CA, USA) under the following two-step cycling program: 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 sec and at 60°C for 1 min. Data analysis was performed based on a Web-Based PCR Array Data Analysis protocol (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) provided by SABiosciences (Qiagen).

**Western blots**

Cell lysates were prepared, resolved on SDS-polyacrylamide gels and transferred to nitrocellulose membranes according to established procedures [13]. Blocking of nonspecific proteins was performed by incubation of the membranes with 5% nonfat dry milk in Tris buffered saline Tween-20 (TBST, pH 8.0) for 2 h at room temperature. Blots were incubated with primary antibodies at 1:1,000 dilution in blocking solution overnight at 4°C. The membranes were washed 3 times with TBST for 10 min and incubated for 1 h with horseradish peroxidase-conjugated secondary antibody at 1:2,500 in 5% milk/TBST. The membranes were then rinsed 3 times with TBST for 10 min and the bands were visualized by enhanced chemiluminescence. After membrane stripping for 10 min with methanol
containing 3% H₂O₂, β-actin was detected in order to serve as an internal loading control.

**Construction of the CCL20 and CXCL8 promoter-luciferase genes**

DNA fragments of the human CCL20 and CXCL8 genes were generated by PCR using genomic DNA isolated from OVCAR-3 cells. Primer sets were designed as follows: 5′-GGATCCGGAAATGTCCCGTGC-3′ for a sense containing a XhoI site and 5′-CTCGAGCTTAATACGACTCACTATAGGGCTGACATGGGGC-3′ for an antisense containing a HindIII site for the CCL20 promoter (−376/+20) and 5′-CACCTCTGATCGTACCTATAGGGCTGACATGGGGC-3′ for a sense containing a XhoI site and 5′-CTCGAGCTTAATACGACTCACTATAGGGCTGACATGGGGC-3′ for an antisense site containing a HindIII site for the CXCL8 promoter (−322/+10). The PCR reaction was performed for 35 cycles at 94°C for 30 sec, 58°C for 30 sec and 74°C for 1 min with a final extension at 74°C for 10 min. The amplified CCL20 and CXCL8 DNA fragments were digested with XhoI and HindIII and the fragments were purified according to the manufacturer's instructions (Gel Extraction System, Qiagen, Valencia, CA). The purified CCL20 and CXCL8 promoter genes were subcloned into the pGL4.12-basic vector (Promega, Madison, WI, USA). The constructs of the CCL20 and CXCL8 promoter-luciferase genes were confirmed by DNA sequencing analysis.

**Transient transfection and luciferase assays**

Human ovarian cancer cells at approximately 50% confluency in 24-well plates were washed once with fresh media without additives and were transiently transfected for 24 h at 37°C using Lipofectamine solution. Transfected cells were treated as outlined in Results and incubated for 6 h. After rinsing cells with ice-cold PBS and adding lysis buffer (Promega, Madison, WI), cell lysates were used for determination of luciferase activity using a microplate luminometer. Luciferase activity, expressed as relative light units, was normalized to measured protein levels.

**Statistical analysis**

Data were analyzed by the paired Student's t-test and one-way analysis of variance (ANOVA) as appropriate. If a statistical significance (P ≤ 0.05) was determined by ANOVA, the data were further analyzed by Tukey's pairwise comparisons to detect specific differences between treatments.

**Results**

**EGF- or TNF-responsive chemokine signature in ovarian cancer cells**

We selected ovarian cancer cell lines OVCAR-3, SKOV-3, CaOV-3 and TOV-21G to determine PCR arrays containing genes that encode human chemokines and chemokine receptors after the addition of EGF or TNF. The present study used the nomenclature of chemokines approved by the IUIS/WHO Subcommittee on Chemokine Nomenclature (2002). The mRNA levels of a panel of 43 chemokines and 19 chemokine receptors were evaluated for each of the 4 cell lines. Based on a Web-Based PCR Array Data Analysis protocol provided by SABiosciences (Qiagen), the absent, low and high expression levels of chemokines were defined as >35, 30–35 and <30 average threshold cycles, respectively.

OVCAR-3 cells highly expressed CCL20, CCL28, CXCL1, CXCL2, CXCL3 and CXCL8. Except for CCL28, all were responsive to EGF or TNF (Figure 1A and Table 1). Although control CCL2 and CXCL16 cytokines were expressed at low levels, they were both highly elevated following the addition of EGF or TNF. The effects on CCL2, CCL20 and CXCL8 levels appeared to be synergistic when both EGF and TNF were added (Figure 1A and Table 1). Although CXCL6, CXCL10 and CX3CL1 were induced by EGF or TNF, overall they had a low expression (Figure 1A). OVCAR-3 cells displayed absent or low chemokine receptor levels. Although CXCR4 was responsive to EGF or TNF, the expression levels post addition of either factor, were still low (Figure 1B). In addition, EGF activated Akt whereas TNF alone activated IκB in OVCAR-3 cells (Figure 1C).

SKOV-3 cells expressed high levels of CCL26, CCL28, CXCL1, CXCL8 and CXCL16; of these, CXCL1 and CXCL8 were responsive to either EGF or TNF (Figure 2A and Table 1). Although CCL20, CXCL2 and CXCL3 were expressed at low levels in the absence of EGF or TNF, they were highly expressed by EGF and TNF. Based on the fact that the level of CCL20 and CXCL8 in SKOV-3 cells expressed to both EGF and TNF were greater than the sum of the levels reached with either EGF or TNF alone, we judged that in these cases, there was a synergistic effect of EGF and TGF in these cells (Figure 2A and Table 1). In SKOV-3 cells chemokine receptor levels were either absent or low and had no responsiveness to either EGF or TNF (Figure 2B). SKOV-3 cells had a constitutively high level of phosphorylated (activated) Akt that did not appear to be influenced by the addition of EGF or TNF. However EGF activated Erk without IκB phosphorylation whereas TNF highly activated IκB and had a small effect on the activation of Erk (Figure 2C).

CaOV-3 cells highly expressed CCL20, CCL25, CCL28, CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, CXCL14 and CXCL16, of which CCL20, CXCL2 and CXCL8 were more responsive to EGF than TNF (Figure 3A and Table 1). CXCL8 appeared to be synergistically elevated in the presence of both EGF and TNF (Figure 3A and Table 1). CaOV-3 cells displayed high basal levels of
CXCR4 and CXCR7 that were not responsive to either EGF or TNF. Although CXCR5 level was low, it was highly expressed in response to EGF or TNF (Figure 3B and Table 1). EGF activated IκB, Akt and Erk whereas TNF activated only IκB and reduced EGF-activated Akt and Erk in these cells (Figure 3C).

Lastly, TOV-21G cells highly expressed CCL2, CCL25, CCL28, CXCL1, CXCL2, CXCL3, CXCL5, CXCL12, CXCL14 and CXCL16, of which CXCL1, CXCL2 and CXCL3 were more responsive to EGF than TNF (Figure 4A and Table 1). Although baseline TOV-21G cellular CXCL8 values were expressed at low levels, it was highly expressed by EGF (Figure 4A and Table 1). TOV-21G cells displayed high levels of CCR10, CXCR4 and CXCR6, which were unresponsive to EGF or TNF (Figure 4B and Table 1). Although CXCR5 was responsive to EGF or TNF, its expression level was still low (Figure 4B and Table 1). TOV-21G cells had constitutively high Akt activation levels. EGF activated IκB and Erk whereas TNF activated only IκB (Figure 4C).

**Confirmation of EGF- or TNF-responsive chemokines in ovarian cancer cells**

Based on chemokines and chemokine receptors influenced by EGF or TNF in PCR array data (Figures 1, 2, 3 and 4 and Table 1), we confirmed EGF- or TNF-responsive chemokines using qRT-PCR with specific chemokine primers. CCL2, CCL20 and CXCL8 were synergistically elevated ($P \leq 0.05$) in response to EGF and TNF in OVCAR-3 cells (Figure 5A). On the other hand, CXCL1, CXCL2 and CXCL3 were more responsive to TNF compared to EGF while CXCL16 responded similarly to both EGF and TNF (Figure 5A). Interestingly, although SKOV-3 cells showed a significant synergistic response of CCL20, CXCL1, CXCL2, CXCL3 and CXCL8 ($P \leq 0.05$) levels to the addition of EGF plus TNF, TNF alone had a greater effect than EGF alone (Figure 5B). Induction levels of CCL20 or CXC8 were larger than those of CXCL1-3 (Figure 5B).

CaOV-3 cells exposed to EGF plus TNF synergistically elevated CXCL8 and CXCR5 ($P \leq 0.05$), but showed a dominant effect of EGF>TNF, when each was added alone (Figure 5C). CCL20 and CXCL2 levels also underwent a greater increase with EGF added alone, than TNF (Figure 5C). Finally TOV-21G cells induced CXCL1-3 and CXCL8 without any apparent synergistic effect in response to EGF plus TNF. They also showed a greater induction by EGF than TNF (Figure 5D). The synergistic responses observed (Figure 5) were consistent with our PCR array data (Table 1).
Characteristics of components related with differential EGF- or TNF-activated Akt, Erk and IkB in ovarian cancer cells

Based on different responses to EGF or TNF in ovarian cancer cells (Figures 1, 2, 3, 4 and 5), we compared those signaling components previously related with EGF- or TNF-activated Akt, Erk and IkB in ovarian cancer cells. We measured and compared ErbB isoforms, Akt, the MAPK pathway (Erk, p38 and SAPK/JNK), IKK isoforms, IkB, and the NF-κB family in nonstimulated ovarian cancer cells and compared their differential expression patterns. All cell lines expressed ErbB1, a specific receptor for EGF; SKOV-3 also highly expressed ErbB2 (Figure 6A). CaOV-3 cells expressed less Akt (Figure 6A), indicating less EGF-mediated activation of Akt (Figure 3C). Erk, p38 and SAPK/JNK expressions were similar between the cell lines (Figure 6B). Interestingly CaOV-3 and TOV-21G cells highly expressed IKKα whereas OVCAR-3 and SKOV-3 cells highly expressed IkB (Figure 6C). In addition, CaOV-3 and TOV-21G cells highly expressed p52 as compared to OVCAR-3 and SKOV-3 cells (Figure 6D). These baseline data support our findings that OVCAR-3 and SKOV-3 cells are more responsive to TNF while CaOV-3 and TOV-21G cells are more responsive to EGF.

CCL20 and CXCL8 promoter activities in response to EGF and TNF in ovarian cancer cells

The regulation of CCL20, CXCL1-3 and CXCL8 is well known [10]. Our findings indicated that the addition of EGF plus TNF produced a synergistic effect on the levels of CCL20 and CXCL8 in OVCAR-3 and SKOV-3 cells (Figure 5). We therefore generated CCL20 and CXCL8 promoters to determine the effects of EGF and TNF on the regulation of CCL20 and CXCL8 at the promoter level. The data show that CCL20 and CXCL8 promoter activities synergistically responded to EGF plus TNF (P ≤ 0.05) in OVCAR-3 cells, although when added separately, TNF had a dominant effect (Figure 7A and 7B). BAY-11-7082 (NF-κB inhibitor) significantly reduced this effect on the CCL20 and CXCL8 promoters in contrast to LY294002 (Akt inhibitor) and PD98059 (Erk inhibitor) (Figure 7 and 7B).

EGF and TNF synergistically induced CXCL8 promoter activity (P ≤ 0.05) and EGF alone had a greater response than TNF alone in CaOV-3 cells (Figure 7B).

| Table 1 EGF- and/or TNF-responsive chemokines and chemokine receptors obtained in ovarian cancer cell lines |
|---------------------------------------------------------------|
| **Chemokine** | **OVCAR-3** | **SKOV-3** | **CaOV-3** | **TOV-21G** |
|----------------|------------|------------|-------------|-------------|
| CCL2           | 2.95       | 7.01       | 12.86       | 1.28        |
| CCL20          | 2.20       | 3.41       | 7.19        | 3.68        |
| CCL25          | 1.02       | 1.37       | 1.43        | 1.31        |
| CCL26          | -1.44      | -1.11      | 1.02        |             |
| CCL28          | 1.77       | 1.55       | 1.42        | -1.06       |
| CXCL1          | 2.53       | 4.38       | 6.48        | 2.64        |
| CXCL2          | 3.43       | 4.99       | 8.97        | 1.87        |
| CXCL3          | 2.81       | 6.73       | 9.68        | 1.45        |
| CXCL5          | 1.28       | -1.00      | 1.33        |             |
| CXCL8          | 3.73       | 4.38       | 11.67       | 6.19        |
| CXCL12         | -1.33      | 1.26       | -1.13       |             |
| CXCL14         | -1.24      | 1.19       | -1.04       | -1.14       |
| CXCL16         | 2.40       | 2.50       | 2.74        | -1.02       |
| Receptor       |            |            |             |             |
| CCR10          | -1.36      | 1.14       | -1.25       |             |
| CXCR4          | 1.32       | 1.70       | 1.62        | 1.38        |
| CXCR5          | 5.24       | 3.33       | 10.63       |             |
| CXCR6          | 1.08       | 1.24       | -1.06       |             |
| CXCR7          | -1.10      | -1.04      | -1.44       |             |

Only PCR array data for highly expressed chemokines and chemokine receptors (below an average threshold cycle of 30) are described above. Values shown represent the fold changes over baseline values, in the presence of EGF, TNF or both (ET). Bold numbers indicate EGF- or TNF-responsive chemokines and chemokine receptors levels that were elevated > 2-fold among highly expressed chemokines. Bold underlined numbers indicate the presence of a significant synergism when both EGF and TNF were added.
LY294002 significantly reduced CCL20 and CXCL8 promoter activities whereas BAY-11-7082 and PD98059 had no effect (Figure 7A and 7B). This fact supported that CaOV-3 cells were more sensitive to EGF > TNF, when each was given alone (Figure 5C).

Although CCL20 was only produced at low levels in TOV-21G cells [even in response to EGF and TNF (Figure 4A)], CCL20 promoter activity responded to both EGF > TNF when each was given alone (Figure 7A). BAY-11-7082 and LY294002 had no effect whereas PD98059 significantly reduced CCL20 promoter activity (Figure 7A). While TOV-21G cells increased CXCL8 promoter activity in response to EGF or TNF, this effect was greater in EGF exposed cells (Figure 7B). LY294002 and PD98059 significantly reduced CXCL8 promoter activity whereas BAY-11-7082 had no effect in these cells (Figure 7B). TNF-dominant responsive cells such as OVCAR-3 and SKOV-3 were found to be sensitive to an NF-κB inhibitor while EGF-dominant responsive cells such as CaOV-2 and TOV-21G were sensitive to Akt or Erk inhibitors.

Discussion

One of the primary findings in this study is that in these four ovarian cancer cell lines, CCL20, CXCL1-3 and CXCL8 were the major chemokines that responded to EGF or TNF by involving NF-κB, Akt and Erk signaling pathways. Particularly, CCL20 and CXCL8 levels were synergistically elevated in response to a combination of EGF plus TNF.

Although the chemokine signature profile was to some degree cell-type specific, the most highly expressed chemokines were as follows: CCL20, CCL28, CXCL1-3, CXCL8 and CXCL16. These experimental findings are supported by clinical data showing that CXCL1 expression levels are greater in ovarian cancer than in normal ovary tissues and are also higher in sera from women with ovarian cancer [18]. CXCL8 has also been shown to be higher in ascites isolated from ovarian cancer patients than in ascites of women with benign tumors [19,20].

We found that CCL28 and CXCL16 were either unresponsive or far less responsive to EGF or TNF. Although CCL28 levels remain unchanged in these ovarian cell lines, TNF has been shown to increase CCL28 in cultured canine keratinocytes [21] and in A549 human airway epithelial-like cells, via NF-κB signaling [22]. These differences indicate that the chemokine network is likely to be differentially regulated in various cell types. In case of CXCL16, only OVCAR-3 cells induced CXCL16 in response to EGF or TNF, although the effect was very small. The effect of TNF on CXCL16 regulation is still
Figure 3 EGF- or TNF-responsive chemokine signatures in CaOV-3 cells. EGF- or TNF-responsive chemokines (A) and chemokine receptors (B) were determined by PCR array. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 h. Values shown are fold changes compared to vehicle controls. After isolating total RNA, a real-time PCR was performed using a customized human chemokine PCR array. Dashed lines indicate the equivalent of 2-fold changes from controls. A chemokine signature with a >2-fold increase was considered as EGF- or TNF-responsive. White, blue, green and red blocks indicate an absent, low, transient (low to high) and high expression level of chemokines, respectively, based on a >35, 30–35, 30–35 to <30 and <30, on average, threshold cycle. An asterisk (*) indicates EGF- or TNF-responsive chemokines with a high expression level (below an average threshold cycle of 30). (C) Effects of EGF or TNF (or both) on IκB, Akt and Erk activation. Cells were treated with EGF (10 ng/ml) or TNF (10 ng/ml) for 0–60 min. Whole cell lysates were prepared and IκB, Akt and Erk activations were confirmed by Western blot analyses. Experiments were performed in duplicate and a representative result is shown.

Figure 4 EGF- or TNF-responsive chemokine signatures in TOV-21G cells. EGF- or TNF-responsive chemokines (A) and chemokine receptors (B) were determined by PCR array. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 h. Values shown are fold changes compared to vehicle controls. After isolating total RNA, a real-time PCR was performed using a customized human chemokine PCR array. Dotted lines indicate the equivalent of 2-fold changes from controls; chemokine signature with a greater than 2-fold increase is recognized as EGF- or TNF-responsiveness. White, blue, green and red blocks indicate absent, low, transient (low to high) and high expression levels of chemokines, respectively, based on a >35, 30–35, 30–35 to <30 and <30, on average, threshold cycle. Asterisk indicates EGF- or TNF-responsive chemokines with a high expression level (below an average threshold cycle of 30). (C) Effects of EGF or TNF on IκB, Akt and Erk activation. Cells were treated with EGF (10 ng/ml) or TNF (10 ng/ml) for 0 to 60 min. Whole cell lysates were prepared and IκB, Akt and Erk activations were confirmed by Western blot analyses. Experiments were performed in duplicate and a representative result is shown.
Figure 5 Confirmation of EGF- or TNF-responsive chemokines in ovarian cancer cell lines. (A) Effects of EGF or TNF on CCL2, CCL20, CXCL1, CXCL2, CXCL3, CXCL8 and CXCL16 by qRT-PCR in OVCAR-3 cells. (B) Effects of EGF or TNF on CCL20, CXCL1, CXCL2, CXCL3 and CXCL8 by qRT-PCR in SKOV-3 cells. (C) Effects of EGF or TNF on CCL20, CXCL1, CXCL2, CXCL8 and CXCR5 by qRT-PCR in CaOV-3 cells. (D) Effects of EGF or TNF on CCL20, CXCL1, CXCL2, CXCL3 and CXCL8 by qRT-PCR in TOV-21G cells. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 h. After isolating total RNA, a qRT-PCR array was performed using specific chemokine primers. An asterisk (*) indicates a significant synergistic effect of the combination of EGF and TNF on chemokine expression (P ≤ 0.05) within each group as monitored by ANOVA and Tukey’s pairwise comparisons. Experiments were performed in triplicate and all data are shown as mean ± SEM.

Figure 6 The baseline expression of signaling components associated with EGF- or TNF-activation. Expression levels of ErbB isoforms and Akt (A), MAPK pathway (B), IKK isoforms and IκB (C), and NF-κB family (D) in OVCAR-3 (OV), SKOV-3 (SK), CaOV3 (Ca) and TOV-21G (TOV) cells. Whole cell lysates were prepared and protein expression levels were confirmed by Western blot analyses. Experiments were performed in duplicate and a representative result is shown.
controversial in other model systems. TNF increased CXCL16 in human gingival fibroblasts [23] whereas it had no effect in human vascular smooth muscle cells [24] or in human bronchial epithelial cells [25]. CXCL16 contains a functional activator protein-1 (AP-1) binding motif, and PI3K inhibitors and a c-Jun N-terminal kinase (JNK) inhibitor attenuated IL-18-mediated AP-1 binding and CXCL16 promoter-reporter activity [26]. These facts suggest that EGF or TNF may increase CXCL16 via PI3K or JNK activation, respectively, in OVCAR-3 cells.

On the other hand, CCL20, CXCL1-3 and CXCL8 were highly responsive to EGF or TNF. Because these chemokines contain κB sites on their promoters [13], NF-κB signaling is likely to play a primary role as a regulator. Because EGF does not directly activate NF-κB signaling in OVCAR-3 and SKOV-3 cells, a TNF-activated NF-κB pathway appears to be more dominant in these cells compared to EGF mediated pathways. Interestingly, EGFR-activated NF-κB was observed in both CaOV-3 and TOV-21G cells, explaining the dominant responsiveness of EGF in these lines. In addition, these cells had high levels of IKKα and p52 and low levels of IkB, supporting the concept that a non-canonical NF-κB pathway was involved in their low response to TNF. On the other hand, OVCAR-3 and SKOV-3 cells had low levels of IKKα and p52 and high levels of IkB, supporting a canonical NF-κB pathway responsible for their dominant response to TNF.

Actually the relationship between EGFR activation and NF-κB signaling is very controversial in other model systems. For instance, heparin-binding EGF-like growth factor (HB-EGF) inhibited NF-κB activation via PI3K-dependent phosphorylation of Akt in cytokine-stimulated intestinal epithelial cells [27]. In contrast, EGF contributed to NF-κB activity in human proximal tubule cells [28] and in pancreatic cancer [29]. In addition, EGF did not activate NF-κB or alter NF-κB activation by TNF in chondrocytes [30]. Despite either

---

**Figure 7** Promoter activities for EGF- or TNF-responsive CCL20 and CXCL8 in ovarian cancer cells. CCL20 promoter activity (A) and CXCL8 promoter activity (B) in response to EGF (E), TNF (T) or both (ET) ± inhibitors for IkB (BAY-11-7082, Bay 2 μM), Akt (LY294002, LY 2 μM) and Erk (PD98059, PD 10 μM) in OVCAR-3, SKOV-3, CaOV3 and TOV-21G cells. After transfection with CCL20 and CXCL8 luciferase vectors overnight, a luciferase assay was performed. Results were normalized to total protein concentrations and expressed as fold increases compared to controls. Different asterisks (*,**,***) indicate significantly increased differences (P ≤ 0.05) within each group by ANOVA and Tukey’s pairwise comparison. A number sign (#) indicates a significant decrease (P ≤ 0.05) compared to EGF and TNF (ET) measures in the absence of inhibitors, as calculated by Student’s t-test. Experiments were performed in triplicate and all data are shown as mean ± SEM.
no or little activation of NF-κB, EGF is likely to broadly induce CCL20, CXCL1-3 and CXCL8 through Akt/Erk activation in ovarian cancer cells. In support of this, EGF was found to activate NF-κB and induce CXCL1 in murine squamous cell carcinoma [31]. The fact that an EGF-induced increase in CXCL1 and CXCL8 was decreased by MAPK inhibitors in ovarian cancer cells [16] indicates involvement of Akt or Erk signaling.

In particular, EGF synergistically induced CCL20 and CXCL8 by cooperating with TNF. CXCL8 is well known to be regulated by NF-κB signaling [32]. In addition to NF-κB signaling, TNF-upregulated CXCL8 is likely to involve JNK and the p38 MAPK pathway [33]. EGF has also been found to induce the release of CXCL8 through signaling pathways involving Erk and P38K in MCF-7 breast carcinoma cells [34]. In addition, EGFR/Erk and AP-1 pathways were found to be involved in MMP12-induced CXCL8 release from the alveolar epithelium [35]. Thus the combination of EGF and TNF in these studies seems to have boosted CXCL8 expression by coordinating NF-κB, Akt and Erk signaling pathways.

Also CCL20 expression is under the direct control of NF-κB in mouse liver [36] and TNF upregulates CCL20 via NF-κB signaling in intestinal epithelial-type cells [37]. The NF-κB site in CCL20 promoter is critical for LDL responsiveness [38]. In addition to NF-κB signaling, the CCAAT/enhancer binding protein β (C/EBPβ) is a critical regulator of CCL20 in normal human keratinocytes [39]. Proinflammatory cytokine IL-6 stimulates CCL20 expression in part through STAT3 activation in primary murine astrocytes [40]. The miR-21 functionally interacts with the 3’UTR of CCL20 mRNA in colorectal cancer cells, resulting in downregulation of CCL20 [41]. IL-17F is able to induce CCL20 via Erk signaling in bronchial epithelial cells [42]. Similarly with TNF, the combination of IL-1 and EGFR ligands synergistically provoked CCL20 in human keratinocytes [43]. Various signaling pathways involved in CCL20 regulation supports the synergistic effects of EGF and TNF on CCL20 expression by collaboratively involving the NF-κB, Akt and Erk signaling pathways.

Thus TNF-dominant responsive cells (OVCAR-3 and SKOV-3) produced a greater synergistic effect on CCL20 and CXCL8 mRNA when compared to EGF-dominant responsive cells (CaOV-2 and TOV-21G cells). This may be due to the fact that CCL20 and CXCL8 promoters contain a κB site as a main responsive element [10]. Furthermore, promoter assays for CCL20 and CXCL8 supported the synergistic effects of EGF and TNF on CCL20 and CXCL8 via collaboration between the NF-κB and Akt/Erk signaling pathways.

Compared to chemokines, it was difficult to find cell-type specific patterns for chemokine receptors in these cell lines. OVCAR-3 and SKOV-3 cells had either no, or a very low expression of chemokine receptors. Also those ovarian cancer cells with a high endogenous expression of TNF, expressed higher levels of CXCR4 than cells with a low TNF expression [11]. Despite a low expression, however, CXCR4 was responsive to EGF or TNF in OVCAR-3 cells. Although a 24 h treatment with EGF enhanced CXCR4 through P38K/Akt signaling in SKOV-3 cells [17], the basal level of CXCR4 was found to be low in these cells. Further, even though CaOV-3 and TOV-21G cells expressed high levels of CXCR4, EGF or TNF had no effect on CXCR4 expression in these cell lines. The low response to TNF in CaOV-3 and TOV-21G cells is likely due to their poor responsiveness of CXCR4 expression. Because TOV-21G cells highly express CXCL12/CXCR4 and CXCL16/CXCR6 axes in spite of a low response to EGF or TNF, these axes may contribute to cancer progression as described by others [44,45].

Interestingly, CXCR5 was responsive to EGF or TNF in CaOV-3 and TOV-21G cells. Although CXCR5 promotes the growth of tumor cells in the liver [46], the role(s) of CXCR5 in ovarian cancer is poorly understood. As the cancer cells tested do not express CXCL13 (a ligand for CXCR5), the novel role of CXCR5 in ovarian cancer cells in response to EGF or TNF may highlight their interaction with immune cells expressing CXCL13 in the tumor microenvironment. Because inflammation-driven ovarian cancer was found to enhance CXCL1-3 expression [10], - targeting CXCR2, a
specific receptor for CXCL1-3, may be a therapeutic strategy as suggested by others [47]. Based on the synergistic increase of CCL20 and CXCL8 in response to EGF and TNF, CCL20 and CXCL8 may be the dominant chemokines found in ovarian cancer cells with abundant TNF, and/or activation of the EGFR. CXCL8 reportedly may function as an important therapeutic target in colorectal cancers [48]. A high expression of CXCL8 was found to be a poor prognostic factor of urothelial bladder cancer [49]. Increased expression levels of CXCL8 may also contribute to the multidrug resistance seen in human breast cancer cells [50]. High expression of CCL20 is also closely associated with poor clinical outcome of patients with gliomas [51] and with a poorer prognosis in patients with hepatocellular carcinoma [52]. The CCL20/CCR6 axis has been shown to promote non-small cell lung cancer progression [53]. Also CCL20 is up-regulated in pancreatic cancer [54] and overexpression of CCL20 in prostate cancer cells promotes tumor growth and invasiveness [55]. Based on these critical roles of CXCL8 and CCL20, high-grade ovarian cancer cells with abundant TNF and EGFR activation may augment these proinflammatory chemokines to provide an inflammatory tumor microenvironment promoting cancer progression and leading to poorer outcomes and an increase in cancer deaths (Figure 8).

Conclusion

Our results indicate that ovarian cancer cells induce CCL20, CXCL1-3 and CXCL8 as the primary chemokines in response to EGF or TNF. Further, CCL20 and CXCL8 can be significantly elevated by the synergistic actions of EGF plus TNF. Targeting these proinflammatory chemokines may support a promising therapeutic strategy for inflammatory ovarian cancer with abundant TNF and EGFR activation pathways.

Competing interests

Authors declare no conflict of interest.

Authors’ contributions

Conceived and designed the experiments: DS and EL. Performed the experiments: DS, SK and YD. Analyzed the data: DS and EL. Contributed reagents/materials/analysis tools: DS, EL and SA. Wrote the paper: DS, EL and SA. All the authors have read and approved the final manuscript.

Acknowledgements

This research was supported in part by NIADDK SC1A089073 (DS), NIGMS SC1 089630 (EL), NCI U54CA163069-02 and NIMHD U54WD007593-04 (SA) from the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH. Suggestions and editorial assistance provided by Dr. Diana Marver is gratefully acknowledged.

Author details

1 Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN, USA. 2 Department of Physiology, Meharry Medical College, Nashville, TN, USA.

References

1. Ness RB, Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. Natl Cancer Inst 1999, 91:1459–1467.
2. Fleming JS, Beaugie DR, Hatch L, Cheneva-Trench G, Tan OT: Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006, 2474–247.
3. Macibó A, Madeddu C: Inflammation and ovarian cancer. Cytokine 2012, 58:133–147.
4. Słodarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al: Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 2006, 5:382–390.
5. Dobrzycka B, Terlikowski SJ, Garbicz M, Nikińska W, Bernacký PS, Nikiński J, et al: Tumor necrosis factor-α and its receptors in epithelial ovarian cancer. Pol J Histochim Cytochem 2009, 43:609–613.
6. Dobrzycka B, Terlikowski SJ, Kowalczik Z, Rinaldi M: Circulating levels of TNF-α and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur J Gynaeco Obstet Gynecol Reprod Biol 2009, 20:131–134.
7. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al: A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012, 72:66–76.
8. Singh R, Lillard JW Jr, Singh S: Chemokines: key players in cancer progression and metastasis. Front Biosci 2011, 16:569–582.
9. Balkwill FR: The chemokine system and cancer. J Pathol 2012, 226:148–157.
10. Son DS, Parl AK, Rice VM, Khabele D: Clinical implications of the erbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008, 1782:232–235.
11. Kulbe H, Hagernann T, Słodarek PW, Balkwill FR, Wilson JL: The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005, 65:10355–10362.
12. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maello MR, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 3662–16.
13. Laffy JM, Wilken JA, Baron AT, Malshe NJ: Clinical implications of the erbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Cancer Biol Ther 2007, 6:1302–1312.
14. Landen CN Jr, Birrer MJ, Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008, 26:995–1005.
15. Siwak DR, Carey M, Hennessey BT, Nguyen CT, McGahren Murray MJ, Nolden M, et al: Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010, 2010:568938.
16. Mascova M, Marshall DJ, Baxter RC: Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res 2006, 66:1376–1383.
17. Guo Z, Cai S, Fang R, Chen H, Du J, Tan Y, et al: The synergistic effects of CXC4R4 and EGFR on promoting EGFR-mediated metastasis in ovarian cancer cells. Colloids Surf B Biointerfaces 2007, 60:1–6.
18. Yang G, Rosen DG, Zhang Z, Baxt RC Jr, Mills GB, Colacino JA, et al: The chemokine growth-regulated oncogene 1 (gro-1) links ras signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 2006, 103:16472–16477.
19. Schuette R, Struyf S, Proost P, Opdamenker G, Laureys G, Verhasselt B, et al: Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002, 277:24594–24599.
20. Nowak M, Glowacka E, Szaflowski M, Szy0 K, Malinowski A, Kulił A, et al: Proinflammatory and immunosuppressive serum, ascites and cyto fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010, 31:375–383.
21. Shibata S, Maeda S, Maeda S, Chikuma N, Kond0 N, Fukata T: Augmentation of CCLI7 and CCL28 gene expression by TNF-α, IL-1β, or IFN-γ in cultured canine keratinocytes. Vet Res 2010, 41:323–426.
22. O’Gorman MT, Jato NA, Lane SJ, Mahon BP: IL-1β and TNF-α induce increased expression of CCL28 by airway epithelial cells via an NFκB-dependent pathway. Cell Immunol 2005, 238:87–96.
23. Hosokawa Y, Hoshikawa I, Ozaki K, Nakae H, Matsu T: CXC chemokine ligand 16 in periodontal diseases: expression in diseased tissues and...
production by cytokine-stimulated human gingival fibroblasts. Clin Exp Immunol 2007, 149:146–154.
24. Wägström D, Olofsson PS, Norgren L, Stenberg B, Sirjö A: The chemokine and scavenger receptor CXCL16/SP-R/PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun 2004, 325:1177–1193.
25. Day C, Patel R, Guillon C, Wardlaw AJ: The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp Lung Res 2009, 35:272–283.
26. Chandrasekhar B, Mummidid S, Valiente AJ, Patel DN, Bailey SR, Freeman GL, et al: The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 2005, 280:26263–26277.
27. Mehta VB, Besner GE: Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-κB activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2005, 175:1911–1918.
28. Haussler U, von Wichert G, Schmid RM, Keller F, Schneider G: Epidermal growth factor activates nuclear factor-κB in human proximal tubule cells. Am J Physiol Renal Physiol 2005, 289:F806–F815.
29. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM: Mitogenic and antiapoptotic role of constitutive NF-κB-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003, 105:735–746.
30. Klooster AR, Bernier SM: Tumor necrosis factor alpha and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte. Arthritis Res Ther 2005, 7:R17–R138.
31. Loukina E, Chen Z, Van Waes C, Dong G: Expression of proangiogenic growth factor Gero 1 in low and high metastatic variants of Pan murine squamous cell carcinoma is differentially regulated by IL-1α, EGF and TGF-β1 through NF-κB dependent and independent mechanisms. Int J Cancer 2001, 94:637–644.
32. Huang S, Robinson JB, Deguzman A, Buccana CD, Fidler I: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000, 60:5354–5359.
33. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M: Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002, 72:647–655.
34. Haim K, Weizenfeld P, Meshal T, Ben-Baruch A: Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasmtologia 2011, 13:20–243.
35. Le Quément C, Gueron I, Gillon JY, Lagente V, Boichot E: Mitogenic and antiapoptotic role of constitutive NF-κB-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003, 105:735–746.
36. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M: Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002, 72:647–655.
37. Fujii H, Hsieh H, Iwasa D, Nakayama T, Fuijwara R, Ohyangi H, et al: Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3α/CCL20 in mucosal epithelial cells through NF-κB. Int Immunol 2001, 13:1255–1263.
38. Calvayrac O, Rodriguez-Calvo R, Alonso J, Orbe J, Martin-Ventura JL, Guadal A, et al: CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF-κB. Arterioscler Thromb Vasc Biol 2011, 31:2733–2741.
39. Sperlberg T, Oldak M, Walach-Rückheim B, Wickenhouser C, Doober J, Pifer H, et al: Human papillomavirus type 8 interferes with a novel C/EBPβ-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration. PLoS Pathog 2012, 8:e1002833.
40. Meares GP, Ma X, Qin H, Berveniste EN: Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 2012, 60:771–781.
41. Vicinus B, Rubie C, Faust SK, Frick VO, Ghajjar P, Wagner M, et al: miR-21 functionally interacts with the 3′UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. Cancer Lett 2012, 316:105–112.
42. Nozato K, Fujita J, Kawaguchi M, Ohara G, Morishima Y, Ishii Y, et al: IL-17F induces CCL20 in bronchial epithelial cells. J Allergy 2011, 2011:257204.
43. Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT: EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol 2011, 131:329–337.
44. Guo L, Cai ZM, Zhang J, Huang Y: Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma. Chin J Cancer 2011, 30:336–343.
45. Reghi E, Kadiwagi S, Yuan J, Santonocosto M, Leblanc P, Ingham R, et al: CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011, 71:5522–5534.
46. Meijer J, Zeelenberg IS, Sipos B, Roos E: The CXCRS chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res. 2006, 66:9576–9582.
47. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, et al: Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012, 122:3127–3144.
48. Ning Y, Lenz HJ: Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets 2012, in press.
49. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NL, Abo DK, et al: Increased expression of MPP-9 and IL-8 are correlated with poor prognosis of bladder cancer. BMC Urol 2012, 12:18.
50. Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q, Zhu J, et al: Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat 2012, 135:757–747.
51. Wang L, Qin H, Li L, Zhang Y, Tu Y, Feng F, et al: Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas. Med Oncol 2012, 29:3491–3497.
52. Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, et al: High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastronc Surg 2012, 16:832–836.
53. Krishberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, et al: Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One 2011, 6:e24856.
54. Rubie C, Frick VO, Ghajjar P, Wagner M, Grimm H, Vicinus B, et al: CCL20/ CCR6 expression profile in pancreatic cancer. J Transl Med 2010, 8:45.
55. Beider K, Abraham M, Begin M, Wald H, Weiss IQ, Wald O, et al: Interaction between CCRX4 and CCL20 pathways regulates tumor growth. PLoS One 2009, 4:e1525.